All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-02-02T15:09:35.000Z

Incidence and risk factors of hemorrhagic events in essential thrombocythemia

Feb 2, 2024
Share:
Learning objective: After reading this article, learners will be able to cite both the incidence and risk factors associated with hemorrhagic events in patients with essential thrombocythemia.

Bookmark this article

Patients diagnosed with essential thrombocythemia (ET) experience thrombocytosis and risk reduction is therefore a key goal for therapeutic intervention. Currently, the main risk stratification model as recommended by the European LeukemiaNet is the International Prognostic Score of thrombosis in ET (IPSET-t); however, to date there has been no specific tool developed to aid in the prediction of hemorrhagic risk. Below, we summarize a publication from Tosoni et al. in Annals of Hematology on a retrospective analysis to define both the incidence and risk factors connected to hemorrhagic events in patients with ET.

Study design1

  • Included 308 ET patients diagnosed between 1996–2022
  • The primary study endpoint was the incidence of thrombotic and hemorrhagic vascular events linked with possible correlations between associated clinical variables and their occurrence.

Results1

Thrombotic events

  • More patients experienced thrombotic events during the course of ET compared with diagnosis (10.4% vs 6.2%).
  • More patients who experienced thrombosis had a high-risk IPSET-t score compared with patients who were high-risk but had no thrombosis at diagnosis (95% vs 47%, p < 0.001).
  • No correlation was found between mutational status and thrombotic risk.

Hemorrhagic events

  • A total of 40 hemorrhagic events were experienced by 35 patients.
  • Risk of hemorrhagic event was increased:
    • in patients at an older age (60) at diagnosis by 2.5-fold after diagnosis vs younger patients (p = 0.032); and
    • in patients with a high-risk IPSET-t score by 4.2-fold after diagnosis vs low/intermediate risk (p = 0.003).
  • The 10- and 20-year cumulative incidence of hemorrhagic events were 6% and 12%, respectively.
  • Hemorrhage-free survival was lower in high-risk IPSET-t patients vs low/intermediate risk (p = 0.002).
  • There was no correlation between incidence of hemorrhagic risk, driver mutation, and Janus kinase 2 variant allele frequency.

Key learnings

  • Highlight the potential use of the IPSET-t model as a global evaluator for vascular events.
  • Limited by its retrospective nature, cohort heterogeneity and small patient number.
  • Future studies should aim to analyze bleeding factors in larger and more homogenous patient cohorts alongside common bleeding classifications to help manage the increased risk of mortality as a result of thrombotic events.

  1. Tosoni L, Liberi M, Morelli G, et al. Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience. Ann of Haem. 2024;103(2):443–448. DOI: 1007/s00277-023-05578-8

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox